Vectura initiates legal proceedings against GSK
GSK accused of patent infringement.
Vectura has received formal notification from GlaxoSmithKline (GSK) that GSK does not wish to exercise the option to take a license to any additional patents under the patent licence and option agreement with Vectura dated 5 August 2010 for GSK's Breo Ellipta/Relvar Ellipta, Anoro Ellipta and Incruse Ellipta products (the 'Ellipta products').
In response to this, Vectura has filed a patent infringement lawsuit against GSK claiming infringement of Vectura's US Patent No. 8,303,991 in the United States District Court for the District of Delaware. Although the lawsuit has been filed, Vectura continues to remain open to finding a mutually acceptable solution to avoid costs and potential uncertainty over royalties that have, up to now, been subject to a cap of £13 million per calendar year.
The separate licence agreement with GSK relating to the legacy Skyepharma dry powder formulation technology used in the Ellipta products is unaffected with the potential for royalty income of up to £9 million per annum.
Patent licence and option-to-licence agreement
In August 2010, GSK and Vectura entered a license and option-to-licence agreement encompassing a number of Vectura patent families relating to various formulation technologies relevant to GSK's Ellipta products. A number of these patents expire in 2016. GSK had the option to extend the term of the agreement by licensing additional patent families on or before 31 July 2016, but has formally notified Vectura that it does not wish to do so.
Despite the notification from GSK, the Directors believe that revenues for the current financial year ending December 2016 remain in line with current expectations.
James Ward-Lilley, Vectura's CEO commented: "As a UK-based R&D collaborator and formulation specialist, the Group undertakes to build strong collaborative partnerships respecting important and valued IP and know how. Vectura has now issued proceedings in the US to enforce its patents relating to these products. Vectura has a robust, diversified business with a series of growing revenue streams from products at relatively early stages of their respective sales trajectories. The focus of the organisation is the progression of the portfolio and leveraging the benefits of the recent merger with Skyepharma including the additional revenues of new product opportunities and delivery of committed cost synergies."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance